Eric D. Hsi
Impact in
- Pathology and Forensic Medicine top 0.02%
- Lymphoma Diagnosis and Treatment
- Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Papers in
-
- Lymphoma Diagnosis and Treatment 283
- Hematology 95
- Acute Myeloid Leukemia Research 73
- Multiple Myeloma Research and Treatments 12
- Co-authors
- Juraj Bodo (35 shared papers)Jaroslaw Pawel Maciejewski (38 shared papers)Bruce D. Cheson (32 shared papers)Raymond R. Tubbs (23 shared papers)Sin‐Ho Jung (25 shared papers)Brian Thomas Hill (21 shared papers)Alexandru Almasan (6 shared papers)Brad L. Pohlman (29 shared papers)
- Journals
- Blood (106 papers)American Journal of Clinical Pathology (43 papers)Modern Pathology (27 papers)The American Journal of Surgical Pathology (21 papers)Archives of Pathology & Laboratory Medicine (16 papers)
- Partner nations
- United StatesItalyCanada
In The Last Decade
Eric D. Hsi
509 papers receiving 23.1k citations
Eric D. Hsi's Hit Papers
Peers
Comparison fields: 5 of 131
- Pathology and Forensic Medicine 10.8k
- Hematology 3.1k
- Genetics 1.5k
- Oncology 2.8k
- Dermatology 971
Countries citing papers authored by Eric D. Hsi
This map shows the geographic impact of Eric D. Hsi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric D. Hsi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric D. Hsi more than expected).
Fields of papers citing papers by Eric D. Hsi
This network shows the impact of papers produced by Eric D. Hsi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric D. Hsi. The network helps show where Eric D. Hsi may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric D. Hsi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 533 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee Hit paper breakdown → | 2022 | 1046 |
| 2 | Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma Hit paper breakdown → | 2017 | 856 |
| 3 | MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Hit paper breakdown → | 2013 | 567 |
| 4 | Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Hit paper breakdown → | 2011 | 518 |
| 5 | The genetic landscape of mutations in Burkitt lymphoma Hit paper breakdown → | 2012 | 485 |
| 6 | CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma Hit paper breakdown → | 2008 | 478 |
| 7 | Genetic heterogeneity of diffuse large B-cell lymphoma Hit paper breakdown → | 2013 | 454 |
| 8 | 2013 | 394 | |
| 9 | ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes Hit paper breakdown → | 2014 | 360 |
| 10 | 2012 | 337 | |
| 11 | 2012 | 328 | |
| 12 | Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Hit paper breakdown → | 2019 | 328 |
| 13 | 2015 | 322 | |
| 14 | 2012 | 298 | |
| 15 | 2011 | 277 | |
| 16 | 1989 | 233 | |
| 17 | 2020 | 205 | |
| 18 | 2016 | 204 | |
| 19 | 2013 | 200 | |
| 20 | 2014 | 187 |
About Eric D. Hsi
Eric D. Hsi is a scholar working on Pathology and Forensic Medicine, Hematology, Genetics, Oncology and Dermatology, having authored 533 papers that have together received 23.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (283 papers), Acute Myeloid Leukemia Research (73 papers), Viral-associated cancers and disorders (29 papers), Chronic Lymphocytic Leukemia Research (26 papers), Cutaneous lymphoproliferative disorders research (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Cell death mechanisms and regulation (13 papers) and Multiple Myeloma Research and Treatments (12 papers). The work is most often cited by research in Pathology and Forensic Medicine (10.8k citations), Hematology (3.1k citations), Genetics (1.5k citations), Oncology (2.8k citations) and Dermatology (971 citations). Eric D. Hsi has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Juraj Bodo, Jaroslaw Pawel Maciejewski, Bruce D. Cheson, Raymond R. Tubbs, Sin‐Ho Jung, Brian Thomas Hill, Alexandru Almasan, Brad L. Pohlman, Jeffrey L. Johnson and Serhan Alkan. Their work appears in journals such as Blood, American Journal of Clinical Pathology, Modern Pathology, The American Journal of Surgical Pathology and Archives of Pathology & Laboratory Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.